EAT is a type of visceral adipose tissue with paracrine and endocrine effects.
3 EAT serves as an energy source for the myocardium and it is known to secrete proatherogenic cytokines.
3 Increased EAT is not only associated with a higher prevalence of CAD but it is also a prognostic parameter for future cardiovascular events, and, eventually, cardiovascular mortality.
4 Hwang et al. 5 have reported that a high epicardial fat volume index determined by computed tomography was an independent risk factor for the future development of non-calcified coronary plaque even after adjustment for traditional cardiovascular risk factors.
In the light of these findings, assessment of EAT by computed tomography might be beneficial as a part of further evaluation for future cardiovascular events. 
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Recent publications related to calcium score (CS) continue to point to flaws in clinical score classifications and reinforce their ability to distinguish the different cardiovascular events risk groups. The role of clinical score reclassification, when CS is implemented, is a warning to its clinical applicability.
Population studies with long periods of follow-up 2-7 have demonstrated that the use of CS is one of the best tools to determine cardiovascular risk, even when compared to other markers. 7 The potential use of CS is not limited to cardiovascular risk evaluation, for it has proven to be a useful tool in the primary prevention and adequate treatment of sub-clinical forms of coronary artery disease. [8] [9] [10] [11] [12] [13] [14] [15] The presence of a zero CS is indicative of a very low risk, often exempting the patient from early preventive treatment with statins.
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On the other hand, in the presence of a CS that is not zero, and especially > 100 Agatston, therapeutic introduction may be recommended, even in patients who do not fit the indication of current guidelines for the use of statins and other medications, such as anti-hypertensives. [10] [11] [12] [13] [14] [15] Important changes in the guidelines can already be seen, putting CS in the recommendation class I for some of its indications. 16 However, there still are some discrepant recommendations, [17] [18] [19] [20] such as in orientations about the beginning of treatment for cardiovascular risk reduction, that still do not include coronary calcification data, even with robust data that support this positioning. [21] [22] Therefore, we believe that in the next few years, this method will take on a growing importance in clinical guidelines, aiding in a more adequate follow-up of low to intermediate risk patients. 
